Reminder of Gossamer Bio Securities Class Action
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 18 hours ago
0mins
Source: Globenewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Gossamer Bio (NASDAQ: GOSS) securities between June 16, 2025, and February 20, 2026, that they must apply to be lead plaintiff by June 1, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that defendants provided overly positive statements regarding Gossamer's Phase 3 PROSERA study while concealing significant adverse facts related to the study design, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its successful track record in this field.
- How to Participate: Investors can visit the Rosen Law Firm website or call toll-free at 866-767-3653 for more information on joining the class action, with no upfront fees required, ensuring the protection of investor rights.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GOSS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GOSS
Wall Street analysts forecast GOSS stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.211
Low
10.00
Averages
12.33
High
15.00
Current: 0.211
Low
10.00
Averages
12.33
High
15.00
About GOSS
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder of Gossamer Bio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Gossamer Bio (NASDAQ: GOSS) securities between June 16, 2025, and February 20, 2026, that they must apply to be lead plaintiff by June 1, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that defendants provided overly positive statements regarding Gossamer's Phase 3 PROSERA study while concealing significant adverse facts related to the study design, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its successful track record in this field.
- How to Participate: Investors can visit the Rosen Law Firm website or call toll-free at 866-767-3653 for more information on joining the class action, with no upfront fees required, ensuring the protection of investor rights.
See More
Gossamer Bio Faces Securities Class Action Lawsuit
- Lawsuit Background: Gossamer Bio, Inc. (NASDAQ:GOSS) is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, involving investors who purchased securities between June 16, 2025, and February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: Following the lawsuit announcement, Gossamer's stock price plummeted by 80%, reflecting market disappointment over the clinical trial results and severely undermining investor confidence, which could lead to further capital outflows.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer violated federal securities laws, particularly regarding disclosures about the PROSERA trial design, and if confirmed, this could expose the company to greater legal liabilities.
- Investor Losses: Investors in Gossamer are encouraged to submit their loss information, and if the company is found to have made misleading statements, it could have long-term implications for its financial health and affect its listing status on Nasdaq.
See More
Gossamer Bio Faces Securities Class Action Lawsuit
- Lawsuit Background: Gossamer Bio, Inc. (NASDAQ: GOSS) is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, involving investors who purchased shares between June 16, 2025, and February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: Following the lawsuit announcement, Gossamer's stock price plummeted by 80%, reflecting market disappointment over the clinical trial results, which severely undermines investor confidence and could impact future financing and business development.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer violated federal securities laws, particularly regarding disclosures about the PROSERA trial design, potentially exposing the company to greater legal risks and financial losses.
- Investor Losses: The lawsuit encourages investors who suffered significant losses during the class period to submit claims, highlighting strong concerns over the company's transparency and compliance, which may affect its future market reputation and investor relations.
See More
Class Action Filed Against Gossamer Bio for Securities Fraud
- Class Action Initiation: Bragar Eagel & Squire has filed a class action lawsuit against Gossamer Bio in the Southern District of California on behalf of investors who purchased securities between June 16, 2025, and February 20, 2026, indicating significant legal risks for the company.
- False Information Allegations: The lawsuit alleges that Gossamer provided false and misleading information regarding its Phase 3 PROSERA study, particularly concerning the control of placebo responses at Latin American testing sites, which led investors to purchase shares at artificially inflated prices.
- Investor Rights Protection: Investors must apply by June 1, 2026, to be appointed as lead plaintiff in the lawsuit, highlighting the potential impact of this case on investor rights and interests.
- Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm specializing in securities, derivative, and commercial litigation, demonstrating its expertise in protecting investor rights and interests.
See More
Gossamer Bio Faces Securities Litigation Investigation
- Litigation Investigation Launched: Faruqi & Faruqi, LLP is investigating potential claims against Gossamer Bio, Inc., particularly regarding false statements related to the adverse results of the PROSERA study announced on February 23, 2026, which may have led to significant investor losses.
- Poor Study Results: Gossamer's Phase 3 PROSERA study failed to meet its primary endpoint, reporting a placebo-adjusted gain of +13.3 meters but not achieving statistical significance under the prespecified alpha level of 0.025, indicating flaws in the study design.
- Stock Price Plummet: Following the study results disclosure, Gossamer's stock price collapsed from $2.13 per share on February 20, 2026, to $0.42 per share, representing a decline of over 80% in a single trading day, severely undermining investor confidence.
- Legal Rights Reminder: Faruqi & Faruqi reminds investors that June 1 is the deadline to apply to serve as lead plaintiff in the federal securities class action, encouraging affected investors to contact legal counsel to discuss their rights.
See More
Reminder for Gossamer Bio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Gossamer Bio securities between June 16, 2025, and February 20, 2026, that they must apply to be lead plaintiff by June 1, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors participating in the lawsuit will not incur any upfront costs, as the law firm operates on a contingency fee basis, which alleviates the financial burden on investors and encourages more victims to seek compensation.
- Lawsuit Background: The lawsuit alleges that Gossamer Bio provided overly positive statements to investors while concealing significant adverse facts related to the study design of its Phase 3 PROSERA study, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and success in this field.
See More
Reminder of Gossamer Bio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Gossamer Bio (NASDAQ: GOSS) securities between June 16, 2025, and February 20, 2026, that they must apply to be lead plaintiff by June 1, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that defendants provided overly positive statements regarding Gossamer's Phase 3 PROSERA study while concealing significant adverse facts related to the study design, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its successful track record in this field.
- How to Participate: Investors can visit the Rosen Law Firm website or call toll-free at 866-767-3653 for more information on joining the class action, with no upfront fees required, ensuring the protection of investor rights.
See More
Gossamer Bio Faces Securities Class Action Lawsuit
- Lawsuit Background: Gossamer Bio, Inc. (NASDAQ:GOSS) is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, involving investors who purchased securities between June 16, 2025, and February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: Following the lawsuit announcement, Gossamer's stock price plummeted by 80%, reflecting market disappointment over the clinical trial results and severely undermining investor confidence, which could lead to further capital outflows.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer violated federal securities laws, particularly regarding disclosures about the PROSERA trial design, and if confirmed, this could expose the company to greater legal liabilities.
- Investor Losses: Investors in Gossamer are encouraged to submit their loss information, and if the company is found to have made misleading statements, it could have long-term implications for its financial health and affect its listing status on Nasdaq.
See More
Gossamer Bio Faces Securities Class Action Lawsuit
- Lawsuit Background: Gossamer Bio, Inc. (NASDAQ: GOSS) is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, involving investors who purchased shares between June 16, 2025, and February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: Following the lawsuit announcement, Gossamer's stock price plummeted by 80%, reflecting market disappointment over the clinical trial results, which severely undermines investor confidence and could impact future financing and business development.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer violated federal securities laws, particularly regarding disclosures about the PROSERA trial design, potentially exposing the company to greater legal risks and financial losses.
- Investor Losses: The lawsuit encourages investors who suffered significant losses during the class period to submit claims, highlighting strong concerns over the company's transparency and compliance, which may affect its future market reputation and investor relations.
See More
Class Action Filed Against Gossamer Bio for Securities Fraud
- Class Action Initiation: Bragar Eagel & Squire has filed a class action lawsuit against Gossamer Bio in the Southern District of California on behalf of investors who purchased securities between June 16, 2025, and February 20, 2026, indicating significant legal risks for the company.
- False Information Allegations: The lawsuit alleges that Gossamer provided false and misleading information regarding its Phase 3 PROSERA study, particularly concerning the control of placebo responses at Latin American testing sites, which led investors to purchase shares at artificially inflated prices.
- Investor Rights Protection: Investors must apply by June 1, 2026, to be appointed as lead plaintiff in the lawsuit, highlighting the potential impact of this case on investor rights and interests.
- Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm specializing in securities, derivative, and commercial litigation, demonstrating its expertise in protecting investor rights and interests.
See More
Gossamer Bio Faces Securities Litigation Investigation
- Litigation Investigation Launched: Faruqi & Faruqi, LLP is investigating potential claims against Gossamer Bio, Inc., particularly regarding false statements related to the adverse results of the PROSERA study announced on February 23, 2026, which may have led to significant investor losses.
- Poor Study Results: Gossamer's Phase 3 PROSERA study failed to meet its primary endpoint, reporting a placebo-adjusted gain of +13.3 meters but not achieving statistical significance under the prespecified alpha level of 0.025, indicating flaws in the study design.
- Stock Price Plummet: Following the study results disclosure, Gossamer's stock price collapsed from $2.13 per share on February 20, 2026, to $0.42 per share, representing a decline of over 80% in a single trading day, severely undermining investor confidence.
- Legal Rights Reminder: Faruqi & Faruqi reminds investors that June 1 is the deadline to apply to serve as lead plaintiff in the federal securities class action, encouraging affected investors to contact legal counsel to discuss their rights.
See More
Reminder for Gossamer Bio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Gossamer Bio securities between June 16, 2025, and February 20, 2026, that they must apply to be lead plaintiff by June 1, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors participating in the lawsuit will not incur any upfront costs, as the law firm operates on a contingency fee basis, which alleviates the financial burden on investors and encourages more victims to seek compensation.
- Lawsuit Background: The lawsuit alleges that Gossamer Bio provided overly positive statements to investors while concealing significant adverse facts related to the study design of its Phase 3 PROSERA study, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and success in this field.
See More
